MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma
Authors:
- Raffaele LicinioRLRaffaele Licinio
- Brian I CarrBCBrian I Carr
- Alfredo Di LeoALAlfredo Di Leo
- Michele BaroneMichele Barone
- 27 April 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 9 (7) , 993-1003
Abstract
Sorafenib is the only approved systemic treatment for advanced hepatocellular carcinoma patients and all the recently published randomized controlled trials on new systemic drugs have been unsuccessful. This is likely due to a lack of understanding of tumor progression, molecular drivers, and liver toxicity, as well as flaws in trial design. An important signaling pathway in hepatocarcinogenesis is the MEK cascade involved in various cellular responses, including adaptation and survival. A key role in this cascade is played by MEK, of which MEK 1/2 represent the prototypes and an interesting target for new oncological drugs. This review analyzes recent developments and future perspectives on the role of MEK inhibitors in hepatocellular carcinoma treatment.Keywords
This publication has 84 references indexed in Scilit:
- MEK and the inhibitors: from bench to bedsideJournal of Hematology & Oncology, 2013
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid TumorsClinical Cancer Research, 2012
- Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory diseaseInvestigational New Drugs, 2012
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinomaActa Oncologica, 2007
- Loss of Raf Kinase Inhibitor Protein Promotes Cell Proliferation and Migration of Human Hepatoma CellsGastroenterology, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005